These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9092414)

  • 1. [Antiplatelet properties of nitrogen monoxide].
    Adrie C
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1527-32. PubMed ID: 9092414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators.
    Salvemini D; Currie MG; Mollace V
    J Clin Invest; 1996 Jun; 97(11):2562-8. PubMed ID: 8647949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endothelial factors and thrombocyte function].
    Schrör K
    Z Kardiol; 1991; 80 Suppl 5():3-6. PubMed ID: 1776333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ADP-induced human platelet aggregation by a new class of soluble guanylate cyclase activators capable of nitric oxide generation.
    Severina IS; Belushkina NN; Grigoryev NB
    Biochem Mol Biol Int; 1994 Aug; 33(5):957-67. PubMed ID: 7987264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term exposure of endothelial cells to molsidomine increases their antithrombogenicity by inducing the production of nitric oxide-related chemical substances.
    Berenger-Bahuet FP; Rolland PH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S98-105. PubMed ID: 2484710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo.
    Gerzer R; Drummer C; Karrenbrock B; Heim JM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S115-9. PubMed ID: 2484688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
    Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
    Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neither endogenous nor inhaled nitric oxide influences the function of circulating platelets in healthy volunteers.
    Albert J; Wall n NH; Li N; Frostell C; Hjemdahl P
    Clin Sci (Lond); 1999 Sep; 97(3):345-53. PubMed ID: 10464060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nitric oxide, from vascular physiology to therapeutics].
    Adnot S; Eddahibi S; Mauran P; Andrivet P; Carville C; Raffestin B
    Arch Mal Coeur Vaiss; 1994 Dec; 87 Spec No 4():41-51. PubMed ID: 7786135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
    Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
    Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nitrates as thrombocyte function inhibitors].
    De Caterina R
    Z Kardiol; 1994 Jul; 83(7):463-73. PubMed ID: 7941647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
    Gordge MP; Hothersall JS; Noronha-Dutra AA
    Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endothelium-derived relaxing factor(s): endogenous nitrates in the circulation?].
    Lüscher TF; Yang Z; Diederich D; Schneider K; von Segesser L; Siebenmann R; Stulz P; Bühler FR
    Schweiz Med Wochenschr; 1988 Nov; 118(46):1724-9. PubMed ID: 3062771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide.
    Klinge JM; Topf HG; Trusen B; Rauh M; Rascher W; Dötsch J
    Crit Care Med; 2003 Jul; 31(7):2010-4. PubMed ID: 12847397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation in vitro and in vivo.
    Apostoli GL; Solomon A; Smallwood MJ; Winyard PG; Emerson M
    J Thromb Haemost; 2014 Nov; 12(11):1880-9. PubMed ID: 25163536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiplatelet effects of nitrate derivatives].
    De Caterina R
    G Ital Cardiol; 1991 May; 21(5):529-41. PubMed ID: 1936757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NO-donors, part 9 : diazeniumdiolates inhibit human platelet aggregation and induce a transient vasodilatation of porcine pulmonary arteries in accordance with the NO-releasing rates.
    Abuo-Rahma Gel D; Horstmann A; Radwan MF; El-Emam A; Glusa E; Lehmann J
    Eur J Med Chem; 2005 Mar; 40(3):281-7. PubMed ID: 15725497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide and regulation of vascular tone: pharmacological and physiological considerations.
    McHugh J; Cheek DJ
    Am J Crit Care; 1998 Mar; 7(2):131-40; quiz 141-2. PubMed ID: 9509227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide as a regulator of prostacyclin synthesis in cultured rat heart endothelial cells.
    Sievi E; Lähteenmäki TA; Alanko J; Vuorinen P; Vapaatalo H
    Arzneimittelforschung; 1997 Oct; 47(10):1093-8. PubMed ID: 9368700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic activity of beta-adrenolytic drug, sotalol.
    Korbut R; Swies J; Marcinkiewicz E; Gryglewski RJ
    J Physiol Pharmacol; 1998 Mar; 49(1):51-60. PubMed ID: 9594410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.